Rubella Virus Vaccine Live

Summary

Rubella Virus Vaccine Live (CHEMBL2109225) is a phase-3 clinical-stage vaccine component; indicated across 3 conditions including chickenpox and meningococcal infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Vaccine component
• Indications: 3 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109225
Name	Rubella Virus Vaccine Live
Type	Vaccine component
Max phase	3

Also known as: Rubella virus vaccine live, RUBELLA VIRUS VACCINE LIVE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chickenpox	3	MONDO:0005700	EFO:0007204
meningococcal infection	3	MONDO:0005373	EFO:0004249
measles	2	MONDO:0004619	EFO:1002025

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00092391	PHASE3	COMPLETED	A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
NCT03630705	PHASE3	COMPLETED	Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico
NCT03691610	PHASE3	COMPLETED	Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
NCT00092404	PHASE2	COMPLETED	Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)
NCT00109278	PHASE2	COMPLETED	A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)
NCT01049035	PHASE2	COMPLETED	A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
NCT04398706	PHASE2	COMPLETED	Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).